|
|
|
市場調查報告書
二肽基肽酶4（DPP4）抑制劑
DPP IV Inhibitors
|
二肽基肽酶4（DPP4）抑制劑 是由出版商Global Industry Analysts, Inc.在2011年09月所出版的。
這份英文市場調查報告書包含Pages: 363 價格從美金4200起跳。
本報告，調查分析全球二肽基肽酶4（DPP4）抑制劑市場的現狀與展望，彙整DPP4抑制劑的機制、糖尿病治療的有效性、主要已上市產品的定位、主要已認可藥劑的檢視與產品線分析、主要地區/國家市場的主要動向、市場規模實績・預測（∼2017年）、吸收合併・合作契約等企業間的動向、主要企業的檔案資料等，由下列摘要形式闡述。
第1章 簡介・調查方式・產品的定義
第2章 産業概要
- 市場展望
- DPP4抑制劑領域的主要事件
- 現在・將來的分析
- 糖尿病患者的增加
- 2型糖尿病的治療：概要
- 抗糖尿病藥物種類的藥劑等級：概要
- 抗糖尿病藥物等級的比較：HbAC1的下降等級別
- DPP4抑制劑：既有方式的補強
- DPP4治療的光明展望
- DPP4抑制劑 vs GLP-1受體作用劑
- GLP-1受體作用劑與DPP4抑制劑的區別
- 新治療領域的探索：吸引醫藥品企業至DPP4市場
- 有效性的極限促進併用產品的使用
第3章 DPP4抑制劑：市場動態
- DPP4抑制劑的領域
- 先進國家的主要已認可DPP4抑制劑
- Januvia：領先全球的DPP4抑制劑
- Januvia・其他DPP4抑制劑：存在非常大的可能性
- Januvia：市佔率減少，不過依然確保市場的領導地位，等
第4章 主要的已認可藥劑的檢視與產品線分析
- Januvia®經銷權 (Merck & Co.)
- Galvus (Novartis)
- Onglyza (Bristol-Myers Squibb and AstraZeneca)
- Tradjenta (Boehringer Ingelheim)
- 主要的已上市產品的比較
- DPP4抑制劑的產品線
第5章 糖尿病的發生率與罹患率
- 全球的真性糖尿病事例：地區別人口結構分析
- 北美
- 歐洲
- 亞太地區
- 中南美
- 其他地區
第6章 DPP4抑制劑：藥劑等級概要
- 血糖恆定的生理學
- 空腹時的血糖恆定
- 進食時的血糖恆定
- 何謂DPP4？
- DPP4抑制劑：簡介
- DPP4抑制劑的機制
- DPP4抑制劑的機制：略圖
- DPP4抑制劑：與其他抗糖尿病藥物的併用
- DPP4抑制劑的優點
- 2型糖尿病：發病率最高的糖尿病
- T2DM生物化學
第7章 產品的認可・上市
第8章 近期的業界動向
第9章 主要企業
第10章 全球市場展望
第11章 美國
第12章 加拿大
第13章 日本
第14章 歐洲
第15章 亞太地區
第16章 其他地區
Abstract
This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs - Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin among others). The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly And Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW
- Market Outlook
- Major Events in the DPP-IV Inhibitor Space
- Current and Future Analysis
- The Diabetic Epidemic
- Type-2 Diabetes Treatment - A Brief Overview
- Overview of Drug Classes in Anti-Diabetic Drugs Category
- Rationale for Use of DPP-4 Inhibitors
- Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
- DPP-4 Inhibitors - Complementing Existing Approaches
- Outlook for DPP-IV Therapies Remains Robust
- DPP-4 Inhibitors versus GLP-1 Receptor Agonists
- Distinction Between GLP-1 Receptor Agonists and DPP-4 Inhibitors
- Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market
- Limited Efficacy Drives Use of Combination Products
3. DPP-IV INHIBITORS - MARKET DYNAMICS
- The DPP-4 Inhibitor Domain
- Select Approved DPP-4 Inhibitors in Developed Markets
- Januvia - The Leading DPP-IV Inhibitor Drug Worldwide
- Huge Potential Exists for Januvia and Other DPP-4 Inhibitors
- Januvia to Concede Market Share; Yet Remain the Market Leader
- "Me-Too" Competition Fails to Halt Januvia's Success
- Galvus Sales Garner Significant Growth
- A Comparison of Januvia and Galvus
- Pharmacological Comparison of Sitagliptin and Vildagliptin
- Anti-Diabetics Arena in a Quandary as Late Stage Development Drug Faces Trouble
- Increasing Competition to Taper Opportunities for Pipeline Drugs
4. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS
- Januvia(r) Franchise (Merck & Co.)
- Table 1: Global Sales of Januvia (Sitagliptin) Franchise by Drug (2007-2010): Value Sales in US$ Million for Januvia and Janumet (includes corresponding Graph/Chart)
- Table 2: Global Sales of Januvia by Region (2007-2010): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
- Table 3: Global Sales of Janumet by Region (2007-2010): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
- Galvus (Novartis)
- Onglyza (Bristol-Myers Squibb and AstraZeneca)
- Table 4: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2009 & 2010): Value Sales in US$ Million for the US and Rest of World (includes corresponding Graph/Chart)
- Tradjenta (Boehringer Ingelheim)
- A Brief Comparison of Select Marketed Drugs
- DPP-IV Inhibitor Pipeline
5. DIABETES INCIDENCE AND PREVALENCE
- Table 5: Worldwide Prevalence of Diabetes Mellitus by Region: 2010 & 2030 (includes corresponding Graph/Chart)
- Diabetes Mellitus Cases Worldwide - A Demographic Analysis by Geographic Region
- North America
- The United States
- Canada
- Mexico
- Table 6: Prevalence of Diabetes Mellitus in North America (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- Europe
- Table 7: Prevalence of Diabetes Mellitus in Europe (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- Asia-Pacific
- Table 8: Prevalence of Diabetes Mellitus in South East Asia (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- Table 9: Prevalence of Diabetes Mellitus in Western Asia (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- South & Central America
- Table 10: Prevalence of Diabetes Mellitus in South & Central America (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- Rest of World
- Table 11: Prevalence of Diabetes Mellitus in Africa (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
- Table 12: Prevalence of Diabetes Mellitus in The Middle East & North Africa (2010 & 2030): Breakdown by Country, Age Group, and Gender (In '000 People & %)
6. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS
- Physiology of Glucose Homeostasis
- Glucose Homeostasis in the Fasting Stage
- Glucose Homeostasis in the Fed Stage
- What is DPP-4?
- Introduction to DPP-4 Inhibitors
- Mechanism of Action of DPP-4 Inhibitors
- Schematic Representation of DPP-IV Inhibitor' Mechanism of Action
- DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications
- Advantages of DPP-4 Inhibitors
- Type-2 Diabetes - The Most Prevalent Form of Diabetes
- Bio-chemistry of T2DM
7. PRODUCT APPROVALS/INTRODUCTIONS
- Boehringer, Eli Lilly Obtain European Marketing Authorization for Trajenta
- Boehringer, Eli Lilly's Tradjenta Receives FDA Approval
- Bristol-Myers and AstraZeneca Launch Kombiglyze(tm) XR in the US
- Bristol-Myers and AstraZeneca Obtain EU Approval for New Saxagliptin Label Update
- Ono Pharmaceutical Obtains Additional Indication for Glactiv in Japan
- Takeda Obtains Label Extension for Nesina in Japan
- AstraZeneca and BMS Obtain FDA Approval for Kombiglyze(tm) XR
- Novartis Obtains Approval for Vildagliptin in Japan
- Ono and Banyu Launch Glactiv in Japan
- Takeda Launches Nesina(r) in Japan
- Merck, Sharp & Dohme Introduces Januvia in China
- Ono and Banyu Receive Japanese Approval for Sitagliptin
- AstraZeneca and Bristol-Myers Receive EU Marketing Authorization for Onglyza
- AstraZeneca and Bristol-Myers Obtain FDA Clearance for Onglyza
- Merck's Janumet(tm) Receives EU Approval
- MSD Pharmaceuticals Introduces Januvia in India
- Merck Launches Januvia in New Zealand
- Novartis Obtains EU Approval for Combination Diabetes Drug - Eucreas
- Novartis' Diabetes Drug - Galvus Receives EU Approval
- MSD's JANUVIA(r) Obtains EU Approval for Treatment of Type 2 Diabetes
- Merck Obtains FDA Approval for Januvia
8. RECENT INDUSTRY ACTIVITY
- Takeda Resubmits 2 NDAs for Alogliptin in the US
- Astellas to Divest DPP-4 Inhibitor Patents to Royal Pharma
- Sun Pharmaceutical Enters into a Partnership Deal with Merck
- Boehringer Ingelheim and Lilly Enter into Licensing Agreement
- Kowa Initiates Phase-II Trial of Anagliptin
- Phenomix Shuts Shop in the Wake of Breakdown of Dutogliptin Deal
- Forest Labs Opts Out of Anti-Diabetic Drug Deal with Phenomix
- Double-Crane and LG Life Sciences Enter Agreement for Sale of LC-15-0444
- Bristol-Myers Squibb Enters into Collaboration with AstraZeneca
- Takeda Terminates Development of TAK 100
- Merck Obtains Positive Opinion from CHMP for Use of sitagliptin with Insulin
- Merck and Cigna Ink "Performance-Based Contract"
- Novartis Terminates Eucreas Development Program in the US
- Chiesi and Phenomix Ink Development and Commercialization Deal for Dutogliptin
- America Stem Cell and Dara Biosciences Sign Material Transfer Agreement
- Egis Acquires Marketing License for Januvia in Hungary
- Novartis Joins Hands with USV to Market Galvus in India
- Merck and Almirall Enter into an Agreement to Commercialize Tesavell in Spain
- Forest Teams Up with Phenomix for Developing DPP-IV Inhibitor - Dutogliptin
- Sanwa Kagaku and Kowa Ink Deal to Co-develop DPP-4 inhibitor - SK-0403
- Novartis' Diabetes Drug Galvus Faces Delay in FDA Approval
9. FOCUS ON SELECT GLOBAL PLAYERS
- Arisaph Pharmaceuticals, Inc. (US)
- AstraZeneca Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
- Bristol-Myers Squibb (US)
- Eli Lilly And Company (US)
- Merck & Co, Inc. (US)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Novartis AG (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
10. GLOBAL MARKET PERSPECTIVE
- Table 13: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 14: World 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 15: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 16: World 10-Year Perspective for DPP-IV Inhibitors by Drug Class - Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin and Others Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
11. THE UNITED STATES
- A. Market Analysis
- Current & Future Analysis
- Diabetes Pandemic in the US
- Non-Insulin Products Dominate the Diabetes Therapeutics Market
- Table 17: US Non-Insulin Anti-Diabetic Market by Drug Class (2010 & 2017): Percentage Breakdown of Revenues for Metformin, DPP-4 Inhibitors, Sulfonylureas, Thiazolidinediones, GLP-1 Analogues, and Others (includes corresponding Graph/Chart)
- DPP-IV Inhibitors All Set to Gain Market Share in Oral Anti-Diabetics
- Januvia Leads the Way, Will Remain the Top Drug Through 2017
- Minimal Differentiation Affects Sales of Onglyza
- Table 18: US Total Prescriptions of Januvia and Onglyza Analyzed in Terms of Total Prescriptions Since Launch in Thousands (includes corresponding Graph/Chart)
- FDA's Issue of Safety Alert on Januvia and Janumet
- Increasing Scrutiny of NDAs Bodes Tough Time for New Drugs
- Product Approvals/Launches
- Strategic Corporate Developments
- Focus on Select Key Players
- B. Market Analytics
- Table 19: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
12. CANADA
- Market Analysis
- Table 20: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
13. JAPAN
- A. Market Analysis
- Current & Future Analysis
- Competition in Japanese DPP-IV Inhibitor Market Heats Up
- Product Approvals/Launches
- Strategic Corporate Developments
- Focus on Select Key Players
- B. Market Analytics
- Table 21: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14. EUROPE
- A. Market Analysis
- Current & Future Analysis
- Treatment Strategies of Type-2 Diabetes in Europe
- Product Approvals/Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 22: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 23: European 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
14a. FRANCE
- Market Analysis
- Table 24: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14b. GERMANY
- A. Market Analysis
- Boehringer Ingelheim GmbH - A Key Player
- B. Market Analytics
- Table 25: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14c. ITALY
- Market Analysis
- Table 26: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14d. THE UNITED KINGDOM
- A. Market Analysis
- Current & Future Analysis
- Blacklisting of Drugs in UK Raises Concerns
- AstraZeneca Plc. - A Key Player
- B. Market Analytics
- Table 27: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
14e. REST OF EUROPE
- A. Market Analysis
- Novartis AG - A Major Player
- B. Market Analytics
- Table 28: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
15. ASIA-PACIFIC
- A. Market Analysis
- Current & Future Analysis
- Overview of Select Markets in the Region
- India
- DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
- Strong Growth Ahead for Anti-Diabetes Products in India
- First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
- China
- China Lags in DPP-4 Inhibitors Market, Bodes Robust Growth Ahead
- Australia
- Rising Incidence of Diabetes
- Diabetes Market - A Window of Opportunity Restricted by PBS
- Korea
- Januvia Franchise Reigns in Korean DPP- IV Market
- Product Approvals/Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 29: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
16. REST OF WORLD
- A. Market Analysis
- Current & Future Analysis
- A Sneak-Peak at Brazilian Diabetes Market
- B. Market Analytics
- Table 30: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
|
 |
